PALI — Palisade Bio Inc
NASDAQ · Healthcare · Biotechnology
$1.96
-$0.00 (-0.26%)
Palisade Bio Inc (PALI) is a biotechnology company listed on NASDAQ. It is led by J. D. Finley, based in 4600 South Syracuse Street, Denver, CO, United States, 80237, with about 14 employees. Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Net income was -$2.9M. PALI currently screens at market cap $316.3M and trailing P/E 15.2.
Use this PALI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PALI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PALI SEC filings page. Lician reads the product cache first so this HTML stays unique to Palisade Bio Inc even when a live quote feed is slow.
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
PALI Key Statistics
Market Cap
$316.28M
Volume
1.61M
Previous Close
$2.10
Day Range
$2.00 – $2.10
P/E Ratio
15.17
P/B Ratio
2.39
EPS
-$10.19
Revenue
$0.00
Net Income
-$14.44M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
14
PALI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $250.00K | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$14.44M | -$12.30M | -$14.26M | -$26.62M |
| EPS (Diluted) | -$10.19 | -$27.01 | -$16.53 | -$169.74 |
Total Assets
$10.88M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$9.82M
Operating Cash Flow
-$12.19M
Free Cash Flow
$0.00
Palisade Bio Inc Company Information
- CEO, CFO & Director
- J. D. Finley
- Headquarters
- 4600 South Syracuse Street, Denver, CO, United States, 80237
- Website
- www.palisadebio.com
- Phone
- 858 704 4900
- IPO / Founded
- 2006-12-20
- Sector
- Healthcare
- Industry
- Biotechnology